Table 5.

Clinicopathological characteristics and their relationships with adjuvant chemotherapy prescription and completion axillary lymph node dissection (N = 253).

Clinicopathological characteristics	Received ACTX	Did not receive ACTX	P-value	Underwent cALND	Did not undergo cALND	P-value
Age						.954†
< 75 years	46	128		7	3
> 75 years	5	74	<.001* †	8	3
Histological subtype						.788 χ2
IDC	45	158		9	10
ILC	6	36		1	1
Other	0	8	.180 χ2	0	0
Tumour stage						.639†
1	21	100		4	4
2	30	102	.182†	6	7
Grade						.477 χ2
1	0	15		0	0
2	44	160		7	11
3	7	27	.257 χ2	3	0
PgR status						.079 χ2
PgR+	41	173		6	10
PgR−	10	29	.386†	4	1
Ki67 proliferation index (N = 42)						.659†
Ki67 ⩽ 14%	6	26		4	28
Ki67 > 14%	1	9	.461†	1	9
Surgery						.308†
BCS	44	175	.551†	8	8
Mastectomy	7	27		2	3
SLNB						<.001* †
Positive SLNB	20	30		10	9
Negative SLNB	31	172	<.001* †	0	0
Oncotype DX Group (N = 82)						N/A
Low risk (< 11)	2	11	.003* χ2	N/A	N/A
Intermediate risk (11-25)	15	36
High risk (> 25)	11	7

Abbreviations: ACTX, adjuvant chemotherapy; BCS, breast conserving surgery; cALND, completion axillary lymph node dissection; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; N/A, not applicable; PgR, progesterone receptor; SLNB, sentinel lymph node biopsy.

χ² denotes chi-square test.

^*denotes statistical significance.

^†denotes Fisher’s exact test.